Broadening our focus in the search for cell transplantation-based glaucoma therapies

Johnson, Thomas V.; Martin, Keith R

doi:10.1038/eye.2011.63

Cited by 1 publication

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-penetrating glaucoma surgeries have a significant IOP reducing effect and offer some advantages over the conventional gold standard trabeculectomy for minimizing postoperative complications, such as excess filtration that may lead to prolonged flat anterior chamber, persistent hypotony and choroidal detachment and bleb-related complications, e.g. encysted bleb that may lead to late failure and bleb-related infections [1–4]. This study showed that there was a significant improvement of visual acuity, a significant reduction in IOP and a significant decrease in the use of antiglaucoma medications between the preoperative and postoperative results in both groups.…”

Section: Discussionmentioning

confidence: 99%

“…The IOP lowering effect of non-penetrating glaucoma surgeries has been found to comparable to, but not better than, trabeculectomy, but non-penetrating surgeries cause fewer surgical complications [2–9]. The IOP lowering effect of Ologen® implant as an adjuvant to trabeculectomy has been confirmed in many studies [1–3, 17].…”

Section: Discussionmentioning

confidence: 99%

“…Viscocanalostomy has fewer complications than trabeculectomy, e.g. bleb leak, hypotony and bleb-related infections [1–4].…”

Section: Introductionmentioning

confidence: 99%

“…The degradation time of this type of implant is around 180 days; this implant consists of porcine based, lyophilized, crosslinked type I atelocollagen (≥ 90%) and glycosaminoglycans (≤ 10%). During trabeculectomy surgery it is placed subconjunctivally and acts as a spacer to mechanically separate the subconjunctival and episcleral tissues to decrease subconjunctival fibrosis [1, 3].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Combined phacoemulsification and viscocanalostomy with Ologen implant versus combined phacoemulsification and viscocanalostomy

et al. 2019

View full text Add to dashboard Cite

BackgroundTo study the efficacy of the biodegradable collagen implant Ologen® as an adjuvant in phaco-viscocanalostomy in patients with coexisting cataract and primary open angle glaucoma.MethodsThis prospective, interventional, randomized clinical study was done at Alpha Vision Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive either phaco-viscocanalostomy (Phacovisco group) (39 eyes) or phaco-viscocanalostomy with Ologen® implant (OloPhacovisco group) (40 eyes). Follow-up period was 2 years. Nd:YAG laser goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.ResultsNo significant operative or postoperative complications (other than failure) were encountered in either group. At 2 years follow-up, the mean IOP level was statistically significantly decreased in the OloPhacovisco group (p = 0.02) and complete success occurred in 23 eyes (59.0%) in the Phacovisco group and in 32 eyes (80.0%) in the OloPhacovisco group. There was a statistically significant higher success rate regarding complete success in patients that received Ologen® implant (p = 0.04).ConclusionsOlogen® implant improved the success rate of phaco-viscocanalostomy. Larger studies with longer follow-up periods may be required to confirm these findings.Trial registrationThis trial was retrospectively registered on 20/12/2018 under the number (NCT03782051).

show abstract

Section: Discussionmentioning

confidence: 99%